A catheter is a thin flexible tube inserted into a blood vessel and used in procedures such as angiography, in which physicians use the catheter in inject dye into the arteries near the heart to illuminate the vessel via X-ray technology. It can also open a valve, enlarge a narrow blood vessel, close a hole in the heart or close off a blood vessel.
The statement, published in Circulation: Journal of the American Heart Association, is a major overhaul of the association’s last statement released in 1998.
“What we can offer patients now, versus just 10 or 15 years ago, is remarkable different,” said lead author, Timothy F. Feltes, MD, chief of Pediatric Cardiology and co-director of The Heart Center at Nationwide Children’s Hospital. “There have been tremendous advances in the procedures, devices, experience and the expertise of the physicians who perform the procedures. As physicians caring for patients with congenital heart disease, we have to look at heart catheterizations a little differently than we have in the past.”
The statement provides an extensive inventory of diagnostic and interventional techniques that are now considered as options for pediatric patients, noting that catheterization procedures carry a degree of risk for patients.
Some of the 22 new therapeutic options for congenital heart disease include catheter-based techniques to improve blood flow through the heart; repair inborn heart defects such as holes in the heart, repair or replace faulty valves; remove arterial blockages and many other conditions, such as malformed heart chambers.
In addition, the statement covers several hybrid procedures that use traditional surgical techniques in combination with catheterization for treating conditions such as hypoplastic left heart syndrome (severe under development of the left side of the heart), stent implementation (to widen arteries and keep them open) and others.
“The take-home message of this statement is that there are numerous condition that are best served by interventional catheterization procedures,” said Dr. Feltes, also chief of pediatric cardiology and professor of pediatrics at The Ohio State University College of Medicine.
The statement is key to cardiologists who treat pediatric defects, because there are few other sources of such information. “By virtue of the relatively small number of children and adolescents with congenital heart disease, it is difficult to design clinical trials. Ideally, you need thousands of patients to compare one treatment versus another. Only one child in 100 is born with heart disease, so it is very unlikely that one center will have more than one patient to do a side-by-side comparison,” said Dr. Feltes.
The Society for Cardiovascular Angiography and Interventions and the American Academy of Pediatrics endorsed the statement.